Compare IDEXX Laboratories, Inc. (IDXX) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Manulife Financial Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Manulife Financial Corporation trades at $42.51 (market cap $69.96B). The key difference: Manulife Financial Corporation is the larger of the two by market cap, and Manulife Financial Corporation pays a 3.14% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MFC | |
|---|---|---|
Market Cap | $44.48B | $69.96B |
Sector | Health | Financials |
52-Week High | $766.68 | $43.39 |
52-Week Low | $520.87 | $29.90 |
Enterprise Value | $45.38B | $66.52B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
MFC trades at $42.83, down 1.29% today, with a bullish technical signal supported by moving averages. The company reported revenue of $53.01B in 2025 and net income of $5.78B, with a P/E of 17.39. Recent news highlights AI advancements and strong Asia performance, while Q1 2026 earnings missed expectations. Analyst consensus is 57% buy with no sell ratings.
Outlook remains positive driven by AI initiatives and Asia growth, but risks include Q1 earnings miss and regulatory scrutiny. The stock offers steady profitability and dividend income, yet faces headwinds from wealth management outflows and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
